Gilead touts Veklury resilience against mutated coronavirus, plots phase 3 for new COVID oral antiviral

Gilead Sciences has new data showing COVID drug Veklury maintained efficacy despite changes in a coronavirus structure it targets, just as the company explores expedited ways to launch a pivotal trial for an investigational oral antiviral.